Abstract
Introduction/BackgroundNiraparib is a poly(ADP-ribose) polymerase inhibitor approved in ovarian cancer with a starting dose of 200 or 300 mg/day via 100 mg capsules and is under investigation in other solid...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have